{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:27:44Z","timestamp":1792420064928,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["SDR 02-237"],"award-info":[{"award-number":["SDR 02-237"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127658","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T02:42:40Z","timestamp":1756262560000},"page":"127658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design"],"prefix":"10.1016","volume":"63","author":[{"given":"Caroline","family":"Korves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kulldorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami S.","family":"Balajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Zwain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector S.","family":"Izurieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.vaccine.2025.127658_bb0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127658_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127658_bb0015","author":"FDA"},{"issue":"33","key":"10.1016\/j.vaccine.2025.127658_bb0020","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1016\/j.vaccine.2022.06.047","article-title":"Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the veterans health administration: self-controlled risk interval analysis","volume":"40","author":"Korves","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127658_bb0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/sim.7536","article-title":"Ghebremichael-Weldeselassie Y, Douglas IJ, Smeeth L, Farrington CP. Investigating the assumptions of the self-controlled case series method","volume":"37","author":"Whitaker","year":"2018","journal-title":"Stat Med"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127658_bb0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7224a2","article-title":"Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022\u2013May 2023","volume":"72","author":"Ma","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127658_bb0035","author":"Department of Veterans Affairs"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127658_bb0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/10543406.2015.1052819","article-title":"Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety","volume":"26","author":"Li","year":"2016","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.vaccine.2025.127658_bb0045","author":"Omicron is Now the Dominant COVID Strain in the U.S"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127658_bb0050","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127658_bb0055","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2025.127658_bb0060","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127658_bb0065","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/bimj.201800019","article-title":"Self-controlled case series studies: just how rare does a rare non-recurrent outcome need to be?","volume":"60","author":"Whitaker","year":"2018","journal-title":"Biom J"},{"key":"10.1016\/j.vaccine.2025.127658_bb0070","series-title":"Self-controlled case series studies: A modelling guide with R","author":"Farrington","year":"2018"},{"key":"10.1016\/j.vaccine.2025.127658_bb0075","author":"Kulldorff"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127658_bb0080","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1038\/s41467-022-33378-7","article-title":"Effectiveness of COVID-19 vaccines against omicron and Delta hospitalisation, a test negative case-control study","volume":"13","author":"Stowe","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127658_bb0085","article-title":"Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study","volume":"379","author":"Ferdinands","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127658_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28391","article-title":"Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US veterans","volume":"4","author":"Young-Xu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127658_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38975","article-title":"Estimated effectiveness of COVID-19 messenger RNA vaccination against SARS-CoV-2 infection among older male veterans health administration Enrollees, January to September 2021","volume":"4","author":"Young-Xu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2025.127658_bb0100","author":"COVID"},{"issue":"48","key":"10.1016\/j.vaccine.2025.127658_bb0105","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.15585\/mmwr.mm7148e1","article-title":"Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September\u2013November 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127658_bb0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s12879-024-09488-6","article-title":"Duration of effectiveness of the COVID-19 vaccine in Japan: a retrospective cohort study using large-scale population-based registry data","volume":"24","author":"Uemura","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127658_bb0115","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.13.2300403","article-title":"COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1\/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022","volume":"29","author":"Laniece Delaunay","year":"2024","journal-title":"Euro Surveill"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127658_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13143","article-title":"Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 omicron variant, US flu VE network","volume":"17","author":"Tartof","year":"2023","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2025.127658_bb0125","series-title":"Validity of the ICD-10-CM diagnosis code to identify patients with COVID-19 in Medicare administrative claims data. Presented at: 40th international conference on Pharmacoepidemiology & Therapeutic Risk Management","author":"Perez-Vila","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127658_bb0130","author":"FDA"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127658_bb0135","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1093\/cid\/ciac234","article-title":"Effects of confounding Bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination Behaviors","volume":"75","author":"Doll","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127658_bb0140","author":"CDC"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127658_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.27241","article-title":"Awareness of SARS-CoV-2 omicron variant infection among adults with recent COVID-19 seropositivity","volume":"5","author":"Joung","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T03:54:44Z","timestamp":1765857284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"alternative-id":["S0264410X25009557"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127658","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127658"}}